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 CASE REPORT 
 An OXA-48-producing  Escherichia coli isolated from a 
Danish patient with no hospitalization abroad 
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 MIKALA  WANG 1 
 From the  1 Department of Clinical Microbiology, Aarhus University Hospital, Aarhus,  2 Division for Epidemiology and 
Microbial Genomics, National Food Institute, Technical University of Denmark, Lyngby, and  3 Department of 
Rheumatology, Aarhus University Hospital, Aarhus, Denmark 
 Abstract 
 Carbapenemase-producing organisms are disseminating globally and are now emerging as a worrying threat in Scandinavia. 
Before August 2013, OXA-48-producing organisms had not been detected in Danish patients. Here we report the isolation 
of an ST746 OXA-48-producing  Escherichia coli with the plasmid pOXA-48a carrying the  bla OXA-48 gene isolated from a 
Danish patient without history of hospitalization abroad. The patient reported tourist travel to Egypt and Turkey. 
The potential acquisition of carbapenemase-producing organisms by ingestion of contaminated food is discussed. 
 Keywords:  Travel-associated spread ,  OXA-48 ,  carbapenem resistance ,  Enterobacteriaceae 
 Introduction 
 Carbapenemase-producing organisms are disseminat-
ing globally and are now emerging as a worrying threat 
in Scandinavia. OXA-48 carbapenemase-producing 
 Enterobacteriaceae were fi rst detected in Istanbul in 
2001 and have migrated from the Middle East and 
from North African countries to Europe [1,2]. OXA-48 
producers can be diffi cult to detect due to low mini-
mum inhibitory concentrations (MICs) to carbapen-
ems and have gained a foothold in many European 
countries [1]. Before August 2013, OXA-48 producing 
organisms had not been detected from Danish patients. 
Here we report the fi nding of an ST746 OXA-48-
producing  Escherichia coli with the plasmid pOXA-48a 
carrying the  bla OXA-48 gene from a Danish patient 
without history of hospitalization abroad. 
 Case report 
 The isolate was obtained from a 64-year-old female 
diagnosed with systemic sclerosis in 1989. Since 
May 2011, the patient had received erythromycin 
250 mg twice daily, in combination with a proton 
pump inhibitor due to involvement of the gastroin-
testinal tract. She had not received immunosuppres-
sive treatment. In February and June 2013, the patient 
was on holiday for a week in Egypt and Turkey, 
respectively. No episodes of diarrhea were reported. 
In June, upon return from Turkey, the patient con-
sulted her general practitioner and was successfully 
treated for an uncomplicated urinary tract infection 
with pivmecillinam, 400 mg three times daily. Unfor-
tunately, no urine was sent for culture before initiat-
ing treatment and urine culture after treatment was 
without growth. In August, 2 months after returning 
from Turkey, culture of urine after an annual fol-
low-up for systemic sclerosis revealed an  E. coli isolate 
resistant to amoxicillin-clavulanate (minimum inhib-
itory concentration (MIC)    16 mg/L) and piperacil-
lin-tazobactam (MIC    32 mg/L). The patient did not 
report symptoms of urinary tract infection. 
 Antimicrobial susceptibility testing was per-
formed by broth microdilution (Sensititre; Trek 
Diagnostics System, East Grinstead, UK), except for 
the MICs of ertapenem and ciprofl oxacin, which 
In
fe
ct
 D
is 
D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
Te
ch
ni
ca
l I
nf
or
m
at
io
n 
Ce
nt
er
 o
f D
en
m
ar
k 
on
 0
7/
31
/1
5
Fo
r p
er
so
na
l u
se
 o
nl
y.
594 A. Gedebjerg et al. 
were determined by Etest (bioM é rieux, Marcy-
I ’ É toile, France). Results were interpreted according 
to EUCAST guidelines (http://www.eucast.org). 
 The MIC of meropenem (MIC    0.5 mg/L) was 
slightly above the EUCAST epidemiological cut-off, 
well within the susceptible range; however, the isolate 
was resistant to ertapenem (MIC    8 mg/L). The 
isolate was susceptible to all cephalosporins tested 
and to ciprofl oxacin (MIC    0.032 mg/L). The MICs 
are shown in Table I. Consistent with previous 
fi ndings [3], the isolate expressed high-level resis-
tance to temocillin by disk diffusion and there was 
no observed synergy between meropenem/boronic 
acid or meropenem/dipicolinic acid. 
 The isolate was subjected to whole genome 
sequencing (WGS). Genomic DNA was extracted 
(DNeasy Blood and Tissue Kit, Qiagen, Copenhagen, 
Denmark) and fragment libraries were constructed 
using the Nextera Kit (Illumina, Little Chesterford, 
UK) followed by 250 bp paired end sequencing 
(MiSeq, Illumina) according to the manufacturer ’ s 
instructions. Multilocus sequence typing (MLST) 
was performed using the MLST web server 
(www.genomicepidemiology.org ) and the ResFinder 
web server (www.genomicepidemiology.org) was 
used to identify acquired antimicrobial resistance 
genes. WGS showed that the  E. coli isolate belonged 
to sequence type ST746 and revealed that the isolate 
harbored  bla OXA-48 and  bla TEM-1 genes. The  bla OXA-48 
gene was carried on an IncL/M-type plasmid show-
ing 100% homology to the sequence of plasmid 
pOXA-48a reported by Poirel et  al. [4], consistent 
with reports suggesting that the spread of OXA-48 
carbapenemase producers is mainly related to 
dissemination of this plasmid [1,2]. 
 Discussion 
 The  E. coli isolate belonged to sequence type ST746, 
a sequence type rarely detected in human clinical 
isolates. Published studies link this sequence type to 
wild birds and poultry [5 – 7]. As the patient had no 
healthcare-related exposure in the visited countries, 
it was suspected that the source of infection could be 
ingestion of contaminated food. Currently, there is 
no systematic testing for carbapenemase-producing 
bacteria in food, but detection of carbapenemases in 
food has been reported recently [8]. Several studies 
suggest a link between human clinical isolates pro-
ducing extended-spectrum beta-lactamases (ESBLs) 
and ESBLs in poultry [9,10], but so far the possibil-
ity of a connection between carbapenemases in food 
and clinical carbapenemase-producing isolates has 
not been investigated. 
 Recent studies have demonstrated that interna-
tional travel is a major risk factor for acquisition of 
ESBL-producing  Enterobacteriaceae , with coloniza-
tion rates up to 46% depending on the geographic 
area visited [11,12]. However, transmission of car-
bapenemase-producing  Enterobacteriaceae has mainly 
been healthcare associated up till now and screening 
procedures have been restricted to patients trans-
ferred from hospitals abroad. In parallel to acquisition 
of ESBL-producing  Enterobacteriaceae , this case and 
recent reports suggest that transmission of carbapen-
emase-producing  Enterobacteriaceae now occurs in the 
community in endemic areas and indicate that tourist 
travel may constitute a risk of colonization with car-
bapenemase-producing  Enterobacteriaceae [13,14]. 
 Adequate screening and detection methods 
for carbapenemase producers, especially the OXA-
48-type carbapenemases, are essential. OXA-48-
producing  Enterobacteriaceae are easily missed as they 
do not grow on selective media for detection of ESBL 
producers and may not be detected due to low car-
bapenem MICs. The  E. coli isolate detected in this 
case was susceptible to cephalosporin and had a 
meropenem MIC well below the clinical breakpoint. 
Carbapenemase production was only suspected due 
to the use of the epidemiological cut-off for mero-
penem in our laboratory. 
 In conclusion, we report a case of acquisition of 
an OXA-48-producing  E. coli after tourist travel to 
endemic areas without any contact with local 
healthcare providers. This case and recent reports 
of acquisition of carbapenemase producers by 
healthy travelers suggest that screening measures 
for international travelers may now be necessary to 
 Table I. Minimum inhibitory concentrations (MICs) of 
antimicrobial agents. 
Antimicrobial agent MIC (mg/L)
Penicillins
Ampicillin    16
Amoxicillin/clavulanate    16
Piperacillin/tazobactam 32
Cephalosporins
Cefepime    1
Cefotaxime    0.25
Cefoxitin 4
Cefpodoxime    0.25
Ceftazidime    0.25
Ceftriaxone    1
Carbapenems
Ertapenem 8
Imipenem 0.25
Meropenem 0.5
Fluoroquinolones
Ciprofl oxacin 0.032
Aminoglycosides
Gentamicin    16
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prevent the spread of carbapenemase-producing 
 Enterobacteriaceae . 
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